How to Get Retatrutide Online in Faro
Retatrutide is an investigational weight-loss medication not yet approved for prescription in the EU, including Faro, Portugal. Hi-Doctor does not offer Retatrutide.

How to Get Retatrutide Online in Faro
Many individuals in Faro, Portugal, are searching for information on how to access Retatrutide online for weight loss. It's important to understand upfront that Retatrutide is currently not approved for prescription in the EU, including Portugal, and is therefore not offered by Hi-Doctor. This powerful new compound is still in clinical trials. However, if you're interested in modern, effective weight-loss treatments, there are proven, EU-approved options available today through an EU-licensed doctor.
What is Retatrutide, and why isn't it a normal option yet?
Retatrutide is an investigational medication that acts as a triple agonist, targeting GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-pronged approach has shown promising results in clinical trials for significant weight reduction. However, despite the excitement, Retatrutide is still in Phase 3 clinical development. This means it has not yet completed the rigorous review process required by regulatory bodies like the European Medicines Agency (EMA) for market authorization in the EU or the FDA in the United States. Until it receives full regulatory approval, it cannot be legally prescribed or dispensed. Attempting to purchase Retatrutide from unregulated online sources carries significant safety risks, as these products may be counterfeit, contaminated, or incorrectly dosed, lacking any medical oversight.
Proven weight-loss medications available online today
While Retatrutide is not yet an option, several highly effective and EU-approved medications are available for weight management, prescribed by licensed doctors based on your individual health profile.
- Ozempic (semaglutide): A GLP-1 receptor agonist, approved for type 2 diabetes but often prescribed off-label for weight loss when medically appropriate.
- Wegovy (semaglutide, higher-dose): The same active ingredient as Ozempic but at a higher dose, specifically approved by the EMA for chronic weight management in eligible patients.
- Mounjaro (tirzepatide): A dual GLP-1 and GIP receptor agonist, approved for type 2 diabetes and also showing significant weight loss benefits, with EMA approval for weight management expected soon.
- Saxenda (liraglutide): A daily GLP-1 receptor agonist, approved for weight management and typically prescribed for patients who meet specific BMI criteria.
How to get a weight-loss prescription online in Portugal
Hi-Doctor provides a straightforward, regulated path to access EU-approved weight-loss medications, connecting you with an EU-licensed doctor from the comfort of your home in Faro.
- Complete an online questionnaire: Spend 2-3 minutes providing your medical history and current health status through our secure platform.
- Doctor reviews your case: An EU-licensed doctor individually reviews your information to determine if a weight-loss medication is safe and appropriate for you.
- Receive your REMPE prescription: If approved, a valid REMPE electronic prescription (recognized EU-wide) is issued within 24 hours. The €25 consultation fee is automatically refunded if treatment is not appropriate.
- Pick up at any EU pharmacy: Download your PDF prescription from your private account or email and present it at any pharmacy in Portugal or any other EU country, thanks to cross-border prescription directive 2011/24/EU.
Why choose Hi-Doctor over unregulated peptide sellers
When considering weight-loss treatments, safety, regulation, and medical oversight are paramount. Hi-Doctor provides a secure, compliant service that stands in stark contrast to the risks associated with unregulated 'research chemicals' or grey-market peptide vendors. We connect you with EU-licensed doctors who conduct individual case reviews, ensuring you receive real medications from real pharmacies. All interactions and data are handled within your private, RGPD-compliant account, offering complete traceability and peace of mind. With over 50,000 patients served and a 4.8 Trustpilot rating, Hi-Doctor prioritizes your health and safety, unlike providers operating without medical oversight.
Frequently asked questions
Is Retatrutide legal to buy online in Spain?
No, Retatrutide is not legally approved for prescription or sale in Spain or any other EU country. Purchasing it from unregulated online sources is illegal and poses significant health risks.
When will Retatrutide be available by prescription?
The exact timeline for Retatrutide's availability by prescription in the EU is uncertain. It must complete all phases of clinical trials and receive approval from the European Medicines Agency (EMA), a process that typically takes several years.
What's the closest approved alternative to Retatrutide?
While no medication is identical to Retatrutide's triple-agonist mechanism, Mounjaro (tirzepatide) is a dual GLP-1/GIP agonist that is currently approved for type 2 diabetes and is expected to receive EMA approval for weight management, making it a very close alternative in terms of efficacy profile.
How much does an online weight-loss consultation cost?
An online consultation with an EU-licensed doctor through Hi-Doctor costs a flat fee of €25. This fee is automatically refunded if the doctor determines that treatment is not appropriate for your case.
Can I use a Hi-Doctor prescription at any pharmacy?
Yes, prescriptions issued by Hi-Doctor's EU-licensed doctors are REMPE electronic prescriptions, valid at any pharmacy in any EU country, including Portugal, under the cross-border prescription directive 2011/24/EU.
Is Hi-Doctor onboarding new specialists for other conditions?
Yes, Hi-Doctor is continuously onboarding new EU-licensed specialists across various conditions. If a specific treatment isn't currently covered, patients can register their interest at hi-doctor.ai to be notified when a relevant doctor becomes available.